Trial · NCT00103506
Adverse events524
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 524
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Velcade (Bortezomib) Monotherapy | 67 | 318 | |
| other | Anaemia | Blood and lymphatic system disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 80 | 318 | |
| other | Leukopenia | Blood and lymphatic system disorders | Velcade (Bortezomib) Monotherapy | 23 | 318 | |
| other | Leukopenia | Blood and lymphatic system disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 28 | 318 | |
| other | Neutropenia | Blood and lymphatic system disorders | Velcade (Bortezomib) Monotherapy | 71 | 318 | |
| other | Neutropenia | Blood and lymphatic system disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 113 | 318 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Velcade (Bortezomib) Monotherapy | 89 | 318 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 104 | 318 | |
| other | Conjunctivitis | Eye disorders | Velcade (Bortezomib) Monotherapy | 17 | 318 | |
| other | Conjunctivitis | Eye disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 24 | 318 | |
| other | Abdominal Pain | Gastrointestinal disorders | Velcade (Bortezomib) Monotherapy | 23 | 318 | |
| other | Abdominal Pain | Gastrointestinal disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 32 | 318 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Velcade (Bortezomib) Monotherapy | 13 | 318 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 24 | 318 | |
| other | Constipation | Gastrointestinal disorders | Velcade (Bortezomib) Monotherapy | 98 | 318 | |
| other | Constipation | Gastrointestinal disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 99 | 318 | |
| other | Diarrhoea | Gastrointestinal disorders | Velcade (Bortezomib) Monotherapy | 122 | 318 | |
| other | Diarrhoea | Gastrointestinal disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 142 | 318 | |
| other | Dyspepsia | Gastrointestinal disorders | Velcade (Bortezomib) Monotherapy | 13 | 318 | |
| other | Dyspepsia | Gastrointestinal disorders | Doxil/Caelyx Plus Velcade (Bortezomib) | 27 | 318 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00103506/events